AP2015008504A0 - Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms - Google Patents

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms

Info

Publication number: AP2015008504A0
Authority: AP; ARIPO
Prior art keywords: myeloprolifarative; neoplasms; treatment; myeloproliferative disorders; telomerase inhibitors
Prior art date: 2012-12-07

Application number

AP2015008504A

Other languages

English (en)

Inventor

Stephen Kelsey

Monic J Stuart

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-07

Filing date

2013-11-15

Publication date

2015-06-30

2013-03-15 Priority claimed from US13/841,711 external-priority patent/US9375485B2/en

2013-11-15 Application filed by Geron Corp filed Critical Geron Corp

2015-06-30 Publication of AP2015008504A0 publication Critical patent/AP2015008504A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Diabetes (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Physiology (AREA)

AP2015008504A 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms AP2015008504A0 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261734941P	2012-12-07	2012-12-07
US201361799069P	2013-03-15	2013-03-15
US13/841,711 US9375485B2 (en)	2012-12-07	2013-03-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P	2013-11-05	2013-11-05

Publications (1)

Publication Number	Publication Date
AP2015008504A0 true AP2015008504A0 (en)	2015-06-30

Family

ID=50883867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2015008504A AP2015008504A0 (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms

Country Status (37)

Country	Link
EP (3)	EP3456333B8 (fr)
JP (6)	JP6433911B2 (fr)
KR (4)	KR20230028590A (fr)
CN (2)	CN104936602B (fr)
AP (1)	AP2015008504A0 (fr)
AU (4)	AU2013356533B2 (fr)
BR (1)	BR112015013260A2 (fr)
CA (2)	CA3188494A1 (fr)
CL (2)	CL2015001530A1 (fr)
CY (2)	CY1122169T1 (fr)
DK (3)	DK3456333T3 (fr)
EA (1)	EA032973B1 (fr)
ES (3)	ES2789176T3 (fr)
FI (2)	FI3646876T3 (fr)
FR (1)	FR25C1016I1 (fr)
HK (1)	HK1210940A1 (fr)
HR (3)	HRP20191784T1 (fr)
HU (4)	HUE045098T2 (fr)
IL (3)	IL280144B2 (fr)
LT (4)	LT3456333T (fr)
MA (2)	MA45504B1 (fr)
ME (1)	ME03538B (fr)
MX (3)	MX372753B (fr)
MY (2)	MY180634A (fr)
NL (1)	NL301326I2 (fr)
NZ (1)	NZ708920A (fr)
PH (2)	PH12019501008A1 (fr)
PL (3)	PL3646876T3 (fr)
PT (3)	PT2928477T (fr)
RS (2)	RS59363B1 (fr)
SG (3)	SG10202103341SA (fr)
SI (3)	SI3646876T1 (fr)
SM (2)	SMT201900567T1 (fr)
TN (1)	TN2015000249A1 (fr)
UA (3)	UA117116C2 (fr)
WO (1)	WO2014088785A1 (fr)
ZA (3)	ZA201504124B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3296312T1 (sl)	2004-07-02	2021-08-31	Geron Corporation	Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
DK3030227T3 (da)	2013-08-07	2020-04-20	Incyte Corp	Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
PT3065828T (pt)	2013-11-06	2019-04-01	Mayo Found Medical Education & Res	Métodos e materiais para tratar malignidades hematológicas
HRP20201218T1 (hr)	2015-04-23	2020-12-11	Geron Corporation	Postupci za pripremu polinukleotida uporabom pripravaka multivalentne kationske soli
EP3318276A1 (fr)	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
CA3069010A1 (fr) *	2017-07-28	2019-01-31	Geron Corporation	Procedes de traitement du syndrome myelodysplasique
IL319432A (en) *	2018-04-30	2025-05-01	Kartos Therapeutics Inc	Methods of treating cancer
AU2019273850B2 (en)	2018-05-25	2024-11-14	Kartos Therapeutics, Inc.	Methods of treating myeloproliferative neoplasms
CA3104537A1 (fr) *	2018-07-31	2020-02-06	Geron Corporation	Methodes d'identification de patients susceptibles de beneficier d'un traitement a l'aide d'un inhibiteur de telomerase
JP7650798B2 (ja)	2018-11-29	2025-03-25	ジェロン・コーポレーション	骨髄異形成症候群を治療する方法
JP7767279B2 (ja)	2019-11-04	2025-11-11	ジェロン・コーポレーション	骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2021157248A (ja) *	2020-03-25	2021-10-07	パイオニア株式会社	状況出力装置
US20220168403A1 (en) *	2020-07-17	2022-06-02	Geron Corporation	Subcutaneous telomerase inhibitor compositions and methods for using same
WO2022159760A1 (fr) *	2021-01-22	2022-07-28	The Regents Of The University Of California	Méthodes de traitement et d'atténuation d'un cancer
WO2024259369A1 (fr) *	2023-06-14	2024-12-19	Rarecells Inc.	Compositions ciblant des cellules géantes dans des troubles sanguins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
AU733610B2 (en)	1996-12-20	2001-05-17	Geron Corporation	Methods for detecting and inhibiting the RNA component of telomerase
US6331399B1 (en)	2000-05-16	2001-12-18	Isis Pharmaceuticals, Inc.	Antisense inhibition of tert expression
JP2007525414A (ja) *	2003-01-31	2007-09-06	ジェシーエルエスオウ	スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
CN1244592C (zh) *	2003-07-11	2006-03-08	暨南大学	抑制白血病细胞端粒酶活性的反义核酸及其应用
NZ545516A (en)	2003-09-09	2009-06-26	Geron Corp	Modified oligonucleotides for telomerase inhibition
US20050282893A1 (en)	2004-01-30	2005-12-22	Au Jessie L	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
SI3296312T1 (sl)	2004-07-02	2021-08-31	Geron Corporation	Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
FR2877013A1 (fr)	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en)	2005-01-21	2006-07-27	Bahou Wadie F	Methods of diagnosing essential thrombocythemia
WO2006113426A2 (fr) *	2005-04-15	2006-10-26	Geron Corporation	Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
EP1876893B1 (fr)	2005-04-15	2012-04-11	Geron Corporation	Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
US20070224598A1 (en)	2006-03-15	2007-09-27	The Methodist Hospital Research Institute	System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en)	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
SI2898887T1 (sl)	2006-10-30	2019-01-31	Geron Corporation	Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka
CN101220044B (zh) *	2008-01-21	2010-06-02	中国药科大学	端粒酶抑制剂及其制备方法和用途

2013
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 IL IL280144A patent/IL280144B2/en unknown
- 2013-11-15 SM SM20190567T patent/SMT201900567T1/it unknown
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Ceased
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active Active
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 IL IL317233A patent/IL317233A/en unknown
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 HU HUE19187756A patent/HUE066402T2/hu unknown
- 2013-11-15 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/fr active Active
- 2013-11-15 SI SI201332080T patent/SI3646876T1/sl unknown
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/fr active Active
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 PH PH1/2019/501008A patent/PH12019501008A1/en unknown
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 PL PL19187756.2T patent/PL3646876T3/pl unknown
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/fr unknown
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/fr not_active Ceased
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 KR KR1020257024576A patent/KR20250114449A/ko active Pending
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/fr active Pending
- 2013-11-15 SM SM20200328T patent/SMT202000328T1/it unknown
- 2013-11-15 MX MX2015007169A patent/MX372753B/es active IP Right Grant
- 2013-11-15 MY MYPI2020000946A patent/MY200076A/en unknown
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 ES ES19187756T patent/ES2982897T3/es active Active
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 HK HK15111700.1A patent/HK1210940A1/xx unknown
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/fr active Active
- 2013-11-15 CA CA2892907A patent/CA2892907C/fr active Active
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active Active
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 UA UAA202100419A patent/UA128370C2/uk unknown
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 PT PT191877562T patent/PT3646876T/pt unknown
- 2013-11-15 HR HRP20240624TT patent/HRP20240624T1/hr unknown
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282B1/en unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
2019
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142C1/en active Active
2021
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja not_active Withdrawn
- 2022-11-11 ZA ZA2022/12327A patent/ZA202212327B/en unknown
2024
- 2024-05-13 AU AU2024203138A patent/AU2024203138A1/en active Pending
2025
- 2025-05-05 NL NL301326C patent/NL301326I2/nl unknown
- 2025-05-06 LT LTPA2025517C patent/LTPA2025517I1/lt unknown
- 2025-05-07 HU HUS2500019C patent/HUS2500019I1/hu unknown
- 2025-05-07 FI FIC20250019C patent/FIC20250019I1/fi unknown
- 2025-05-07 FR FR25C1016C patent/FR25C1016I1/fr active Active
- 2025-05-12 JP JP2025080100A patent/JP2025109842A/ja active Pending

Also Published As

Publication number	Publication date
JP2022050537A (ja)	2022-03-30
HRP20240624T1 (hr)	2024-08-02
IL317233A (en)	2025-01-01
PL3646876T3 (pl)	2024-07-22
UA128370C2 (uk)	2024-06-26
EP3646876B1 (fr)	2024-02-14
TN2015000249A1 (en)	2016-10-03
ES2982897T3 (es)	2024-10-18
KR20210107906A (ko)	2021-09-01
CN111617252A (zh)	2020-09-04
EP2928477A4 (fr)	2016-09-21
WO2014088785A8 (fr)	2015-07-16
LT3456333T (lt)	2020-06-25
CN104936602B (zh)	2020-07-17
KR102662590B1 (ko)	2024-05-03
KR20230028590A (ko)	2023-02-28
MA45504A1 (fr)	2020-05-29
HUE049858T2 (hu)	2020-11-30
SG10201802926XA (en)	2018-05-30
RS59363B1 (sr)	2019-11-29
EA201590878A1 (ru)	2016-04-29
PL2928477T3 (pl)	2020-03-31
ZA202212327B (en)	2025-03-26
IL280144B1 (en)	2025-01-01
CL2015001530A1 (es)	2016-03-28
HUS2500019I1 (hu)	2025-05-28
JP2025109842A (ja)	2025-07-25
HRP20200993T1 (hr)	2020-11-27
HUE045098T2 (hu)	2019-12-30
ME03538B (fr)	2020-07-20
AU2013356533A1 (en)	2014-06-12
CA2892907A1 (fr)	2014-06-12
HK1212226A1 (en)	2016-06-10
CY1123206T1 (el)	2021-10-29
MX2020003276A (es)	2020-07-20
WO2014088785A1 (fr)	2014-06-12
ZA202108991B (en)	2023-05-31
MX372753B (es)	2020-06-26
DK3646876T3 (da)	2024-05-06
AU2020267142C1 (en)	2024-08-08
AU2024203138A1 (en)	2024-07-25
SG11201504383TA (en)	2015-07-30
MA38193B1 (fr)	2018-12-31
EP3456333B1 (fr)	2020-04-01
PT2928477T (pt)	2019-10-25
JP2016504307A (ja)	2016-02-12
EP3646876A1 (fr)	2020-05-06
CA2892907C (fr)	2023-03-21
JP2022179684A (ja)	2022-12-02
EP3456333A1 (fr)	2019-03-20
IL239266A0 (en)	2015-07-30
FIC20250019I1 (fi)	2025-05-07
EP2928477B1 (fr)	2019-07-24
SI3646876T1 (sl)	2024-07-31
SI3456333T1 (sl)	2020-10-30
JP2018035196A (ja)	2018-03-08
ZA201504124B (en)	2017-05-31
FR25C1016I1 (fr)	2025-06-20
CY1122169T1 (el)	2020-11-25
NZ748134A (en)	2020-10-30
MY200076A (en)	2023-12-06
IL280144A (en)	2021-03-01
AU2018282364A1 (en)	2019-05-23
KR20150091130A (ko)	2015-08-07
KR20250114449A (ko)	2025-07-29
CA3188494A1 (fr)	2014-06-12
JP6433911B2 (ja)	2018-12-05
UA126015C2 (uk)	2022-08-03
EP3456333B8 (fr)	2020-05-13
ES2789176T3 (es)	2020-10-26
DK3456333T3 (da)	2020-05-18
HK1210940A1 (zh)	2016-05-13
KR102294819B1 (ko)	2021-09-01
SMT202000328T1 (it)	2020-07-08
EP2928477A1 (fr)	2015-10-14
MA38193A1 (fr)	2017-12-29
LT2928477T (lt)	2019-10-10
LT3646876T (lt)	2024-05-10
NL301326I2 (nl)	2025-07-31
PL3456333T3 (pl)	2020-09-21
MY180634A (en)	2020-12-03
IL239266B (en)	2019-11-28
JP7288098B2 (ja)	2023-06-06
BR112015013260A2 (pt)	2018-02-06
EA032973B1 (ru)	2019-08-30
DK2928477T3 (da)	2019-10-07
AU2013356533B2 (en)	2018-09-27
RS60401B1 (sr)	2020-07-31
MX2015007169A (es)	2016-03-31
SI2928477T1 (sl)	2019-11-29
FI3646876T3 (fi)	2024-05-14
PH12019501008A1 (en)	2022-11-14
AU2020267142A1 (en)	2020-12-03
MX2022015437A (es)	2023-01-11
IL280144B2 (en)	2025-05-01
UA117116C2 (uk)	2018-06-25
LTPA2025517I1 (fr)	2025-05-26
MA45504B1 (fr)	2021-10-29
CN104936602A (zh)	2015-09-23
JP6998191B2 (ja)	2022-02-04
NZ708920A (en)	2020-08-28
AU2020267142B2 (en)	2024-05-16
PT3456333T (pt)	2020-06-01
PH12015501282A1 (en)	2015-08-24
HRP20191784T1 (hr)	2019-12-27
CL2017002156A1 (es)	2018-05-04
HUE066402T2 (hu)	2024-07-28
SG10202103341SA (en)	2021-05-28
PH12015501282B1 (en)	2015-08-24
JP2020041001A (ja)	2020-03-19
ES2744790T3 (es)	2020-02-26
SMT201900567T1 (it)	2019-11-13
PT3646876T (pt)	2024-05-15

Publication	Publication Date	Title
ZA202108991B (en)	2023-05-31	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
IL283943B1 (en)	2023-04-01	Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders
IL266582A (en)	2019-07-31	Preparations and methods for the treatment of hemoglobin diseases
IL239355A0 (en)	2015-07-30	Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
ZA201607980B (en)	2022-04-28	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP2890440A4 (fr)	2016-06-08	Dispositifs et procédés pour le traitement d'une maladie vasculaire
ZA201408055B (en)	2016-03-30	Compositions and methods for the treatment of local pain
IL234841A0 (en)	2014-12-31	Administration forms of halofuginone and methods of use
IL235127A (en)	2017-12-31	Hpn-100 for use in the treatment of nitrogen-related diseases
ZA201501503B (en)	2016-01-27	Bio-inoculant and use thereof for treatment of effluents
ZA201408060B (en)	2016-03-30	Compositions and methods for the treatment of neurological disorders
PL2846805T3 (pl)	2019-05-31	Leczenie uzależnień i zaburzeń kontroli impulsów za pomocą inhibitorów PDE7
ZA201408061B (en)	2016-04-28	Compositions and methods for the treatment of neurological disorders
HUE043518T2 (hu)	2019-08-28	Függõség és impulzuskontroll zavarok kezelése PDE-7-inhibitorok alkalmazásával